(262 days)
Not Found
No
The description focuses on the physical components and mechanism of action (cryogenic freezing) and does not mention any software, algorithms, or data processing that would indicate AI/ML.
Yes
The device is described as being used to "destroy tissue," "produce lesions in peripheral nervous tissue... for the blocking of pain," and for "the relief of pain and symptoms associated with osteoarthritis of the knee." These are all therapeutic applications.
No
Explanation: The iovera system is described as a "portable cryogenic surgical device used to destroy tissue and/or produce lesions in nervous tissue" and its intended uses are to "destroy tissue during surgical procedures" and "produce lesions in peripheral nervous tissue for the blocking of pain" and "relief of pain and symptoms associated with osteoarthritis of the knee". While a diagnostic block is performed prior to using the device (to confirm candidacy), the device itself is for treatment, not diagnosis.
No
The device description clearly outlines multiple hardware components including a Handpiece, Charging Dock, Smart Tips, and a Cartridge (Nitrous Oxide). It is a physical medical device that utilizes software for user feedback and control, but it is not solely software.
Based on the provided information, the iovera system is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening.
- Iovera System's Function: The iovera system directly interacts with the patient's body by applying cold to destroy tissue or block pain in peripheral nerves. It is a surgical and therapeutic device, not a device that analyzes samples outside the body.
- Intended Use: The intended use clearly states it's used to "destroy tissue during surgical procedures" and "produce lesions in peripheral nervous tissue... for the blocking of pain." This is a direct treatment application.
- Device Description: The description details a system that delivers cold directly to the target site within the body.
Therefore, the iovera system falls under the category of a therapeutic or surgical device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The iovera? system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera" system is not indicated for treatment of central nervous system tissue.
Product codes
GXH
Device Description
The ioveras system is a portable cryogenic surgical device used to destroy tissue and/or produce lesions in nervous tissue creating a nerve block through application of extreme cold to the selected site. The device is based on introduction of a Smart Tip internally cooled by the cryogenic fluid (nitrous oxide, N2O) to a selected area. The Smart Tip is cooled by the Joule-Thomson Effect and/or Latent Heat of Vaporization. The ioveraº system may be used in conjunction with a standard off-the-shelf nerve stimulator device in applications where precise nerve location is desired.
The device is comprised of four main components:
- A reusable Handpiece
- A Charging Dock
- An assortment of single-patient use Smart Tips
- A Cartridge (Nitrous Oxide)
The iovera Handpiece is battery powered and provides feedback to the user during device preparation and use. The Handpiece connects to both the Cartridge and to the Smart Tip. The user activates a treatment cycle through a control on the Handpiece, which starts and stops the treatment. The Handpiece also contains LEDs for providing feedback to the user when the device is ready to use. The Charging Dock stores the Handpiece between uses and provides power for charging the battery.
An assortment of Smart Tips is available for the iovera system. All Smart Tip needles are made of stainless steel and have a closed-end that fully contains the cryogen so that it does not enter the target tissue. The Smart Tip is the only patient contacting component of the iovera° system. The user removes the Smart Tip from the sterile packaging and attaches it to the Handpiece.
The ioveras system uses a commercially available nitrous oxide cylinder. The Cartridge is filled with pure N2O.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
peripheral nervous tissue, knee
Indicated Patient Age Range
36 to 75 years
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical Testing: This was a multi-center, prospective, randomized, double-blind, sham-treatment controlled trial.
Sample size: 121 subjects were treated with the iovera system and 59 subjects were treated with a sham device, with ages ranging from 36 to 75 years, for a total of 180 subjects.
Key results: The primary endpoint (superiority of the iovera° treatment over sham treatment for reducing pain and symptoms due to osteoarthritis in the knee as assessed by the Total WOMAC scale from baseline to Day 30) was met, p=0.001. Subjects treated with the iovera° system reported substantially more pain and symptom relief as subjects treated with the sham device (55% improvement versus 33% improvement). Secondary endpoints were also met, including statistically significant superiority of iovera° treatment over sham treatment for relief of pain and symptoms due to osteoarthritis of the knee on the Total WOMAC scale (pain, stiffness, function) at Day 60 and a statistically significant number of patients reported clinically significant pain relief (30% reduction in WOMAC pain score) through 90 days after treatment with the iovera° system.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Reduction in pain and symptoms on Total WOMAC scale 30 days post-treatment: Iovera treatment group N=121: -73.311, Sham control group (n=59): -42.18
Percentage of patients reporting 30% improvement in pain and symptoms on Total WOMAC scale post-treatment:
30 days: Iovera: 74.58%, Sham: 44.83%
60 days: Iovera: 76.79%, Sham: 56.90%
90 days: Iovera: 80.18%, Sham: 54.39%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 882.4250 Cryogenic surgical device.
(a)
Identification. A cryogenic surgical device is a device used to destroy nervous tissue or produce lesions in nervous tissue by the application of extreme cold to the selected site.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features the department's name encircling a symbol of three stylized human profiles facing right. The profiles are stacked on top of each other, creating a sense of depth and unity. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 24, 2017
Myoscience, Inc. Tracey Henry General Manager 46400 Fremont Blvd Fremont, California 94538
Re: K161835
Trade/Device Name: ioveraº System Regulation Number: 21 CFR 882.4250 Regulation Name: Cryogenic Surgical Device Regulatory Class: Class II Product Code: GXH Dated: February 17, 2017 Received: February 23, 2017
Dear Ms. Henry:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Michael J. Hoffmann -S
for
Carlos L. Peña. PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K161835
Device Name ioveraº system
Indications for Use (Describe)
The iovera? system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera" system is not indicated for treatment of central nervous system tissue.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Section 5: 510(k) Summary
Device Information:
| Category | Comments |
|---|---|
| Sponsor / Submitter: | Myoscience, Inc |
| 46400 Fremont Blvd | |
| Fremont, CA 94538 | |
| Ph: 510.933.1500 | |
| Fax: 410.933.1501 | |
| Correspondent Contact | |
| Information: | Tracey Henry |
| General Manager, Myoscience, Inc | |
| Telephone: 510.933.1510 | |
| Email: thenry@myoscience.com | |
| Device Common Name: | Cryogenic surgical device |
| Device Classification & Code: | Class II, GXH |
| Device Classification Name: | Cryosurgical unit and accessories (21 CFR 882.4250) |
| Device Trade Name: | iovera° system |
a. Predicate Device Information:
| 510(k) Number | Product | Sponsor |
|---|---|---|
| K142866 | iovera o system | Myoscience, Inc |
b. Date Summary Prepared
15 February 2017
c. Description of Device
The ioveras system is a portable cryogenic surgical device used to destroy tissue and/or produce lesions in nervous tissue creating a nerve block through application of extreme cold to the selected site. The device is based on introduction of a Smart Tip internally cooled by the cryogenic fluid (nitrous oxide, N2O) to a selected area. The Smart Tip is cooled by the Joule-Thomson Effect and/or Latent Heat of Vaporization. The ioveraº system may be used in conjunction with a standard off-the-shelf nerve stimulator device in applications where precise nerve location is desired.
Device Design
The device is comprised of four main components:
-
- A reusable Handpiece
-
- A Charging Dock
-
- An assortment of single-patient use Smart Tips
-
- A Cartridge (Nitrous Oxide)
The iovera Handpiece is battery powered and provides feedback to the user during device preparation and use. The Handpiece connects to both the Cartridge and to the Smart Tip. The user activates a treatment cycle through a control on the Handpiece, which starts and stops the treatment. The Handpiece also contains LEDs for providing feedback to the user when the device is ready to use. The Charging Dock stores the Handpiece between uses and provides power for charging the battery.
4
An assortment of Smart Tips is available for the iovera system. All Smart Tip needles are made of stainless steel and have a closed-end that fully contains the cryogen so that it does not enter the target tissue. The Smart Tip is the only patient contacting component of the iovera° system. The user removes the Smart Tip from the sterile packaging and attaches it to the Handpiece.
The ioveras system uses a commercially available nitrous oxide cylinder. The Cartridge is filled with pure N2O.
Device Functionality/Scientific Concepts
The device functionality is based on the user introducing the Smart Tip to the selected treatment area; unwanted tissue or the target nervous tissue. The user then initiates the flow of cryogen by pressing the on/off button. Liquid cryogen flows from the Handpiece into the closed-end Smart Tip. The Smart Tip is cooled by the Joule-Thomson Effect and/or Latent Heat of Vaporization; as the liquid cryogen expands into a gas, the temperature drops around the external surface of the Smart Tip causing the surrounding tissue to freeze. The treatment is completed after a preprogrammed amount of time at which time the user can safely remove the Smart Tip.
d. Indications for Use
The iovera system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera system is not indicated for treatment of central nervous system tissue.
The Indications for Use statement for the subject device has been expanded to include "for the relief of pain and symptoms associated with osteoarthritis of the knee." This additional wording adds specificity to the already cleared indication. Clinical data demonstrate that this specific use does not affect the safety or effectiveness of the iovera system when used as labeled. There were no new questions of safety or effectiveness raised.
e. Comparison of Technological Characteristics with the Predicate Device
There are no differences in technological characteristics, as summarized below, and therefore no new or different questions of safety and effectiveness for the subject device are raised.
| Technological Characteristics | |
|---|---|
| Predicate Device (K142866) | Subject Device |
| Cryogenic device | Same |
| Nitrous oxide coolant, pressurized cylinder | Same |
| Reusable handpiece, battery powered | Same |
| Single use tip for subdermal cooling, EO sterilized | Same |
| Charging dock | Same |
| Sensors, monitor nitrous oxide deliver and rate of cooling | Same |
| Smart Tip Needle Length: 6 – 55mm (0.2 – 2.2 in) Size: Ø.31 – .72mm (25 – 30 gauge) Patient contacting materials: | |
| Closed sharp cutting and blunt tip Stainless Steel needle | Same |
5
f. Performance Data
The following performance data were provided in support of the substantial equivalence determination.
| Bench Testing | No bench testing was necessary for the expanded indications for use. |
|---|---|
| Preclinical | |
| Testing | |
| Submitted: | No preclinical testing was deemed necessary for the expanded indications for |
| use. | |
| Clinical Testing | |
| Submitted: | Clinical testing demonstrating the safety and effectiveness of the iovera° |
| system for the relief of pain and symptoms associated with osteoarthritis | |
| of the knee was submitted. | |
| Study Design: | |
| This was a multi-center, prospective, randomized, double-blind, sham- | |
| treatment controlled trial. The treating Investigator and Subject were blinded | |
| to study treatment. Each Subject was followed a minimum of 120 days post- | |
| treatment. Eligible subjects were diagnosed with Grade II or III osteoarthritis | |
| of the knee (Kellgren-Lawrence classification grading scale) and washed out | |
| of all pain medication. A local anesthetic was used to create a diagnostic | |
| block of the infrapatellar branch of the saphenous nerve, as assessed by a | |
| 50% decrease in VAS pain upon standing from a seated position or walking | |
| up stairs, to confirm that the subject was a candidate for treatment. | |
| 121 subjects were treated with the iovera system and 59 subjects were | |
| treated with a sham device, with ages ranging from 36 to 75 years. Data | |
| from all 180 subjects enrolled were collected and analyzed. The primary | |
| endpoint (superiority of the iovera° treatment over sham treatment for | |
| reducing pain and symptoms due to osteoarthritis in the knee as assessed by | |
| the Total WOMAC scale from baseline to Day 30) was met, p=0.001. | |
| Subjects treated with the iovera° system reported substantially more pain and | |
| symptom relief as subjects treated with the sham device (55% improvement | |
| versus 33% improvement). | |
| Secondary endpoints were also met, including statistically significant | |
| superiority of iovera° treatment over sham treatment for relief of pain and | |
| symptoms due to osteoarthritis of the knee on the Total WOMAC scale | |
| (pain, stiffness, function) at Day 60 and a statistically significant number of | |
| patients reported clinically significant pain relief (30% reduction in | |
| WOMAC pain score) through 90 days after treatment with the iovera° | |
| system. |
6
| | | Iovera
treatment
group
N=121 | Sham
control
group
(n=59) |
|------------------------------------------------------------------------------------------------------------------------|---------|---------------------------------------|------------------------------------|
| Reduction in pain and
symptoms on Total WOMAC
scale 30 days post-treatment | | -73.311 | -42.18 |
| Percentage of patients
reporting 30% improvement
in pain and symptoms on
Total WOMAC scale post-
treatment | 30 days | 74.58% | 44.83% |
| | 60 days | 76.79% | 56.90% |
| | 90 days | 80.18% | 54.39% |
1 LS Means and p-value were obtained by fitting an ANCOVA model with treatment as factor and WOMAC baseline score as a covariate.
There were no serious device-related or procedure-related adverse events. All device-related adverse events were as anticipated per the device labeling. A summary of adverse reactions, including site-specific reactions and/or known effects from cryoanalgesia (e.g., bruising, swelling, redness) which lasted longer than 30 days follows.
| Adverse reactions | Iovera | Sham |
|---|---|---|
| N=121 | N=59 | |
| Numbness | 18 (14.8%) | 1 (1.7%) |
| Tenderness upon palpation | 14 (11.6%) | 8 (13.6%) |
| Local pain | 8 (6.6%) | 4 (6.8%) |
| Altered sensation/ localized dysethesia | 3 (2.5%) | 2 (3.4%) |
| Tingling | 3 (2.5%) | 1 (1.7%) |
| Swelling | 3 (2.5%) | 3 (5.1%) |
| Bruising | 3 (2.5%) | 2 (3.4%) |
| Itching | 2 (1.6%) | 0 |
| Vasovagal response | 1 (0.8%) | 0 |
| Knee pain | 1 (0.8%) | 2 (3.4%) |
| Redness/inflammation | 1 (0.8%) | 1 (1.7%) |
| Pain, aggravated | 0 | 1 (1.7%) |
g. Conclusion
Use of the already cleared ioveraº system in the Clinical Study described herein has shown that the device can be used safely and effectively, within its intended use, to provide relief for pain and symptoms associated with osteoarthritis of the knee. Substantial equivalence to the predicate device has been established, therefore, as there was no change to the intended use or the technological characteristics of the device, and data from the Clinical Study demonstrate safety and efficacy; the primary and secondary endpoints were met and there were no new questions of safety or effectiveness.